Liangding D. Hu

8 East Street
Beijing, 100071, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 33 publications

Base-resolution DNA methylome of human MDS hematopoietic stem cell reveals TET2-GFI1 epigenetic axis repressing MDS.

Base-resolution DNA methylome of human MDS hematopoietic stem cell reveals TET2-GFI1 epigenetic axis repressing MDS.

Journal: Immunity & inflammation

Published: January 12, 2026

Clinical observation of posttransplant lymphoproliferative disorder in a single center

Clinical observation of posttransplant lymphoproliferative disorder in a single center

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: January 05, 2026

First report of donor-derived active multiple myeloma from one AML patient after allogeneic stem cell transplantation.

First report of donor-derived active multiple myeloma from one AML patient after allogeneic stem cell transplantation.

Journal: Leukemia & lymphoma

Published: December 04, 2025

Blastic plasmacytoid dendritic cell neoplasm secondary to acute myeloid leukemia with shared mutations in TET2 and DNMT3A: a case report and literature review.

Blastic plasmacytoid dendritic cell neoplasm secondary to acute myeloid leukemia with shared mutations in TET2 and DNMT3A: a case report and literature review.

Journal: Frontiers in immunology

Published: June 29, 2025

Isolated CNS B lymphoid/myeloid bilineage relapse following allogeneic hematopoietic stem cell transplantation in adult acute myeloid leukemia with KMT2A::MLLT1 rearrangement.

Isolated CNS B lymphoid/myeloid bilineage relapse following allogeneic hematopoietic stem cell transplantation in adult acute myeloid leukemia with KMT2A::MLLT1 rearrangement.

Journal: Leukemia & lymphoma

Published: February 10, 2025

Efficacy and safety of human umbilical cord-derived mesenchymal stem cells versus placebo added to second-line therapy in patients with steroid-refractory acute graft-versus-host disease: a multicentre, randomized, double-blind, phase 2 trial.

Efficacy and safety of human umbilical cord-derived mesenchymal stem cells versus placebo added to second-line therapy in patients with steroid-refractory acute graft-versus-host disease: a multicentre, randomized, double-blind, phase 2 trial.

Journal: BMC medicine

Published: June 16, 2024

Ruxolitinib plus steroids for acute graft versus host disease: a multicenter, randomized, phase 3 trial.

Ruxolitinib plus steroids for acute graft versus host disease: a multicenter, randomized, phase 3 trial.

Journal: Signal transduction and targeted therapy

Published: May 22, 2024

Human umbilical cord-derived mesenchymal stromal cells for the treatment of steroid refractory grades III-IV acute graft-versus-host disease with long-term follow-up.

Human umbilical cord-derived mesenchymal stromal cells for the treatment of steroid refractory grades III-IV acute graft-versus-host disease with long-term follow-up.

Journal: Frontiers in immunology

Published: May 22, 2024

Editorial: Novel mechanism and strategies to overcome relapse after allogeneic stem cell transplantation.

Editorial: Novel mechanism and strategies to overcome relapse after allogeneic stem cell transplantation.

Journal: Frontiers in immunology

Published: June 26, 2023

Expert consensus on microtransplant for acute myeloid leukemia in elderly patients -report from the international microtransplant interest group.

Expert consensus on microtransplant for acute myeloid leukemia in elderly patients -report from the international microtransplant interest group.

Journal: Heliyon

Published: January 27, 2023

Efficacy and safety of human umbilical cord-derived mesenchymal stem cells (hUC-MSC PLEB001) for the treatment of grade II-IV steroid-refractory acute graft-versus-host disease: a study protocol for a multicenter, randomized, double-blind, placebo-controlled, phase II trial.

Efficacy and safety of human umbilical cord-derived mesenchymal stem cells (hUC-MSC PLEB001) for the treatment of grade II-IV steroid-refractory acute graft-versus-host disease: a study protocol for a multicenter, randomized, double-blind, placebo-controlled, phase II trial.

Journal: Trials

Published: July 31, 2022

Allogeneic haematopoietic stem cell transplantation with decitabine-containing preconditioning regimen in TP53-mutant myelodysplastic syndromes: A case study.

Allogeneic haematopoietic stem cell transplantation with decitabine-containing preconditioning regimen in TP53-mutant myelodysplastic syndromes: A case study.

Journal: Frontiers in oncology

Published: April 25, 2022

Showing 1-12 of 33

Last Updated: 09/26/2026